Mysthenia gravis is which type of hypersensitivity-
**Core Concept**
Mysthenia gravis is an autoimmune disease characterized by the production of antibodies against acetylcholine receptors at the neuromuscular junction, leading to muscle weakness and fatigue. This condition is a classic example of an immune-mediated disorder where the body's immune system mistakenly attacks its own tissues.
**Why the Correct Answer is Right**
The correct answer is related to the pathophysiology of myasthenia gravis, where autoantibodies bind to the nicotinic acetylcholine receptors (nAChRs) on the postsynaptic membrane of the neuromuscular junction. This binding reduces the number of functional acetylcholine receptors available for neurotransmitter binding, leading to impaired neuromuscular transmission and muscle weakness. The autoantibodies in myasthenia gravis are typically of the IgG type, which can cross the placenta and cause fetal neuromuscular blockade.
**Why Each Wrong Option is Incorrect**
* **Option A:** Myasthenia gravis is not a type of Type I hypersensitivity reaction, which typically involves IgE antibodies and the release of histamine from mast cells.
* **Option B:** Myasthenia gravis is not a type of Type II hypersensitivity reaction, which typically involves IgG or IgM antibodies and the activation of complement, leading to cell lysis or phagocytosis.
* **Option C:** Myasthenia gravis is not a type of Type III hypersensitivity reaction, which typically involves the formation of antigen-antibody complexes that deposit in tissues and activate complement.
**Clinical Pearl / High-Yield Fact**
Myasthenia gravis often coexists with other autoimmune disorders, such as thyroiditis, rheumatoid arthritis, and lupus, and patients may also have thymic hyperplasia or thymoma.
**Correct Answer: B. Type II hypersensitivity. This is a correct answer as myasthenia gravis is a classic example of a Type II hypersensitivity reaction, where autoantibodies bind to the acetylcholine receptors on the neuromuscular junction and cause impaired neuromuscular transmission.**